Accessibility Menu
Onconetix logo

Onconetix(NASDAQ) BWV

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-100%
1 Month-7%
Onconetix last closing stock price
MetricPriceDate
Last closeUSD 0.882026-07-22
Onconetix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.75%USD 0.772026-07-15
1 month-7.25%USD 0.952026-06-22
3 month-86.79%USD 6.662026-04-23
Year to date-98.87%USD 78.002025-12-31
1 year-99.53%USD 188.502025-07-22
3 year-100%USD 195,500.002023-07-21
Since inception-100%USD 9,757,921.942022-02-18

Onconetix Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$735.20K

Net Income (TTM)

-$9.70M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Mar 9, 2024

BWV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Onconetix

Onconetix develops blood tests to help doctors diagnose prostate cancer earlier. Its main product, Proclarix, aims to reduce unnecessary biopsies for men. The company also partners with labs to expand access to its diagnostic tools.

Products and Services

  • Proclarix: Blood test for prostate cancer, used by doctors to assess risk and guide biopsy decisions.
  • Development Services (100% of development revenue in 2025): Research and diagnostic support for partners, mainly Immunovia.
  • Licensing: Agreements with labs like LabCorp to distribute Proclarix in the U.S.
  • Decision Support Tools: Software to help doctors interpret test results and manage prostate cancer care.

Growth and Expansion

  • Acquired Proteomedix in December 2023, adding Proclarix to its portfolio.
  • Formed exclusive U.S. commercialization partnership with LabCorp in 2023 for Proclarix, with an amendment in December 2025.
  • Signed licensing agreement with Immunovia in 2025 for pancreatic cancer diagnostics.
  • Abandoned vaccine and ENTADFI drug programs in late 2023 to focus on diagnostics.
  • Pending acquisition of Realbotix Corp. announced in February 2026.

What Makes Onconetix Stand Out

Onconetix focuses on non-invasive, blood-based cancer diagnostics that integrate multiple biomarkers for higher accuracy. Its products are included in major clinical guidelines and use standard lab equipment, making adoption easier for hospitals. The company relies on strategic partnerships for global reach and leverages exclusive patents for its technology.

Five Things You Need to Know

  • Revenue was $815,371 in 2025, down 67.7% from 2024.
  • Gross profit was $632,913 in 2025, down 40.0% from 2024.
  • Operating loss improved to $(17.9) million in 2025 from $(56.5) million in 2024.
  • Cash balance was $5.2 million at December 31, 2025; not enough for one year of operations.
  • Immunovia accounted for most revenue in 2025, showing high customer concentration.

Bottom Line

Onconetix has shifted from drug and vaccine development to focus on cancer diagnostics. The company’s future depends on expanding its diagnostic products and managing financial risks.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

David Allan White, MBA

Website

www.onconetix.com

Headquarters

Cincinnati, OH 45202, US

BWV Financials

Key Financial Metrics (TTM)

Gross Margin

79.63%

Operating Margin

-922.72%

Net Income Margin

-1319.55%

Return on Equity

-105.46%

Return on Capital

-112.92%

Return on Assets

-65.41%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$585.43K

Operating Income

-$15.51M

EBITDA

-$11.80M

Operating Cash Flow

-$9.80M

Capital Expenditure

$0.00

Free Cash Flow

-$9.80M

Cash & ST Invst.

$3.72M

Total Debt

$289.92K

Onconetix Performance Analysis

Onconetix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 58,465N/A
20242024-12-31USD 2,524,1164217.3%
20252025-12-31USD 815,371-67.7%
Onconetix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.8%
Q32025-09-30185.1%
Q42025-12-31-0.0%
Q12026-03-31-92.9%
Onconetix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -187,243.10200.9%
20232023-12-31USD -371,662.5098.5%
20242024-12-31USD -91,170.36-75.5%
20252025-12-31USD -828.15-99.1%
Onconetix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3072.3%
Q32025-09-30-626.7%
Q42025-12-31-56.5%
Q12026-03-3131.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$21.46K

-78.9%

Gross Profit

-$1.66K

-103.6%

Gross Margin

-7.71%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

12

N/A

Net Income

-$4.21M

+50.7%

EBITDA

$5.40K

+8.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.72M

+135.6%

Total Debt

$289.92K

-96.8%

Accounts Receivable

$43.73K

+168.4%

Inventory

$137.64K

-11.6%

Long Term Debt

$18.31K

N/A

Short Term Debt

$271.61K

-97.0%

Return on Assets

-65.41%

N/A

Return on Invested Capital

-57.65%

N/A

Free Cash Flow

-$2.12M

-6.1%

Operating Cash Flow

-$2.12M

-6.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIVSVivoSim Labs, Inc.
$0.46+2.49%
IDRAIdera Pharmaceuticals, Inc.
$0.43-23.04%
LSTALisata Therapeutics, Inc.
$2.20-1.79%
QTTBQ32 Bio Inc.
$15.08-2.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%

Questions About BWV

What is the current price of Onconetix?

Onconetix is trading at N/A per share.

What is the 52-week range for Onconetix?

Over the past 52 weeks, Onconetix has traded between N/A and N/A.

How much debt does Onconetix have?

As of the most recent reporting period, Onconetix reported total debt of $289.92K.

How much cash does Onconetix have on hand?

Onconetix reported $3.72M in cash and cash equivalents in its most recent financial results.

What is Onconetix’s dividend yield?

Onconetix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services